The updated Renal Prognostic Graded Assessment (GPA) is a valid instrument for estimating survival in patients with renal cell carcinoma and brain metastases who have been treated with gamma knife radiosurgery (GKRS).
Why this matters
Between 8–28% of people with renal cell carcinoma develop brain metastases. The incidence of brain metastasis has been growing in this population as detection methods become more sensitive and systemic treatments extend survival.
The Renal GPA is a widely used risk score for estimating survival in patients with renal cell carcinoma and brain metastases. The score was recently updated based on data from a heterogeneously-treated cohort from 2006–2015. However, the updated score has not been sufficiently validated in patients treated with GKRS.